Biogen Inc. (NASDAQ:BIIB) Given Average Recommendation of “Moderate Buy” by Brokerages

Biogen Inc. (NASDAQ:BIIB) has earned a consensus rating of “Moderate Buy” from the twenty-nine brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $215.8077.

A number of equities research analysts have recently commented on BIIB shares. The Goldman Sachs Group increased their price objective on Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Piper Sandler reiterated an “overweight” rating and set a $225.00 price objective (up from $214.00) on shares of Biogen in a research report on Friday, May 15th. Mizuho increased their price objective on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Citigroup increased their target price on Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Finally, Argus upgraded Biogen to a “hold” rating in a report on Thursday, April 9th.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $195.34 on Friday. Biogen has a one year low of $121.05 and a one year high of $205.97. The stock has a fifty day moving average of $187.60 and a 200-day moving average of $183.33. The company has a market capitalization of $28.84 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.72 and a beta of 0.20. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm earned $3.02 EPS. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts anticipate that Biogen will post 14.18 EPS for the current fiscal year.

Institutional Trading of Biogen

A number of hedge funds have recently modified their holdings of BIIB. Caprock Group LLC purchased a new stake in shares of Biogen during the third quarter worth $742,000. Leuthold Group LLC purchased a new stake in shares of Biogen during the third quarter worth $3,294,000. Generali Investments Management Co LLC raised its holdings in shares of Biogen by 408.2% during the third quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock worth $1,397,000 after acquiring an additional 8,008 shares in the last quarter. SG Americas Securities LLC increased its position in Biogen by 1,793.8% during the fourth quarter. SG Americas Securities LLC now owns 183,829 shares of the biotechnology company’s stock worth $32,352,000 after buying an additional 174,122 shares during the last quarter. Finally, TD Asset Management Inc increased its position in Biogen by 12.7% during the third quarter. TD Asset Management Inc now owns 161,195 shares of the biotechnology company’s stock worth $22,580,000 after buying an additional 18,168 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s salanersen won FDA Breakthrough Therapy Designation for SMA, with early phase 1b data suggesting meaningful motor improvements and a once-yearly dosing profile that could make the therapy stand out commercially. BIIB’s Next-Gen SMA Therapy Salanersen Wins FDA’s Breakthrough Tag
• Positive Sentiment: Biogen also highlighted progress on BIIB115 in post-gene therapy SMA, adding to investor optimism that the company has multiple shots on goal in a key neurodegeneration market. Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
• Positive Sentiment: Biogen and UCB presented additional data on dapirolizumab pegol in lupus, showing reduced flare rates and lower steroid use, which supports the drug’s potential in a large autoimmune market. UCB and Biogen build steroid-sparing case for lupus drug
• Neutral Sentiment: Biogen is also facing legal overhang after law firms announced investor investigations and fraud-related claims, which could keep sentiment cautious even as pipeline news improves. BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
• Neutral Sentiment: A separate investor alert from Pomerantz also flagged a claims investigation into Biogen, adding another potential risk factor, though it does not yet indicate any formal enforcement action. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.